Altered MEF2C regulation has been implicated as driver of cancer development [40], and it acts as an oncogene for immature T-cell acute lymphoblastic leukaemia [41], myeloid leukaemia [42], hepatocellular carcinoma [43], and pancreatic ductal adenocarcinoma [44]. The gene discussed is MEF2C; the disease is myeloid leukemia.